Paper Details

  1. Home
  2. Paper Details

Role for 5-day, once-daily extended-release clarithromycin in acute bacterial exacerbation of chronic bronchitis.

Author: BusmanTodd A, GotfriedMark, NorrisSandra, NotarioGerard F

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Clarithromycin is typically prescribed for a week or longer to treat acute bacterial exacerbations of chronic bronchitis (ABECB). However, studies on other antibiotics suggest that shorter treatment courses may be just as effective, with fewer side effects, better adherence, greater patient satisfaction, and lower costs.
Paper Details　
Original Abstract of the Article :
Clarithromycin is commonly dosed for 7 or more days in patients with acute bacterial exacerbation of chronic bronchitis (ABECB). Studies with other antibiotics have shown equivalent efficacy, reduced/similar frequency of adverse events, improved adherence and patient satisfaction, and lower treatmen...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1185/030079906X162827

データ提供：米国国立医学図書館（NLM）

Shorter Treatment Duration for Acute Bacterial Exacerbation of Chronic Bronchitis

Chronic bronchitis is a common respiratory ailment that can lead to recurring episodes of acute bacterial exacerbation (ABECB), characterized by increased cough, phlegm production, and shortness of breath. While clarithromycin is frequently prescribed for 7 or more days to treat ABECB, this study explores the effectiveness of a shorter, 5-day treatment course. The authors investigated the efficacy and safety of a once-daily, extended-release formulation of clarithromycin, comparing it to traditional longer treatment durations. Their findings suggest that a shorter treatment course with extended-release clarithromycin may be just as effective, while potentially reducing adverse events and improving patient adherence.

Shorter Treatment: A Win-Win for Patients

This research indicates that a shorter treatment course of 5 days, with extended-release clarithromycin, can be equally effective in treating ABECB compared to longer durations. This could be a game-changer for patients, minimizing treatment burden and potentially reducing side effects. The study also highlights the importance of patient adherence and satisfaction, crucial factors for successful treatment outcomes.

Breathing Easier with Shorter Treatment

This study provides valuable insight for patients struggling with ABECB. A shorter treatment duration with extended-release clarithromycin could lead to faster symptom relief and improved quality of life. Discuss with your doctor whether this approach is suitable for your condition, as it might offer a more convenient and potentially less burdensome treatment option.

Dr. Camel's Conclusion

Like a camel trekking across the desert, patients with chronic bronchitis may experience the arduous journey of repeated ABECB episodes. This study provides a welcome respite, suggesting that a shorter treatment duration with extended-release clarithromycin could alleviate the burden of lengthy antibiotic regimens. It's like finding a shortcut through the desert, offering a more efficient and potentially less tiring path towards recovery.

Date :
  1. Date Completed 2007-03-15
  2. Date Revised 2016-11-24
Further Info :

Pubmed ID

17288699

DOI: Digital Object Identifier

10.1185/030079906X162827

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.